No connection

Search Results

BRK-B vs HQL

BRK-B
Berkshire Hathaway Inc.
NEUTRAL
Price
$479.75
Market Cap
$1.03T
Sector
Financial Services
AI Confidence
85%
HQL
Abrdn Life Sciences Investors
BULLISH
Price
$17.56
Market Cap
$534.0M
Sector
Financial Services
AI Confidence
75%

Valuation

P/E Ratio
BRK-B
15.46
HQL
6.29
Forward P/E
BRK-B
22.06
HQL
--
P/B Ratio
BRK-B
0.0
HQL
1.01
P/S Ratio
BRK-B
2.79
HQL
275.47
EV/EBITDA
BRK-B
-2.12
HQL
--

Profitability

Gross Margin
BRK-B
26.15%
HQL
100.0%
Operating Margin
BRK-B
32.96%
HQL
-346.83%
Profit Margin
BRK-B
18.03%
HQL
4415.74%
ROE
BRK-B
9.81%
HQL
17.59%
ROA
BRK-B
5.11%
HQL
-0.43%

Growth

Revenue Growth
BRK-B
-0.7%
HQL
-69.9%
Earnings Growth
BRK-B
-2.5%
HQL
259.4%

Financial Health

Debt/Equity
BRK-B
0.19
HQL
--
Current Ratio
BRK-B
7.07
HQL
0.73
Quick Ratio
BRK-B
6.62
HQL
0.71

Dividends

Dividend Yield
BRK-B
--
HQL
12.76%
Payout Ratio
BRK-B
0.0%
HQL
65.23%

AI Verdict

BRK-B NEUTRAL

The deterministic health profile is weak, highlighted by a Piotroski F-Score of 3/9, indicating deteriorating operational efficiency and profitability trends. While the company maintains a fortress balance sheet with a Debt/Equity ratio of 0.19 and a Current Ratio of 7.07, the stock is trading at a significant premium to its growth-based intrinsic value of $217.21. Negative YoY revenue and earnings growth, coupled with a bearish technical trend, offset the positive analyst sentiment and long-term historical performance.

Strengths
Exceptional liquidity with a Current Ratio of 7.07
Very low leverage (Debt/Equity 0.19)
Strong operating margins at 32.96%
Risks
Significant overvaluation relative to intrinsic value ($479.75 vs $217.21)
Negative YoY earnings growth (-2.50%) and revenue growth (-0.70%)
Weak Piotroski F-Score (3/9) suggesting declining financial health trends
HQL BULLISH

HQL presents as a deep-value opportunity, anchored by a stable Piotroski F-Score of 6/9 and a significant valuation gap, with a current price of $17.56 trading well below its Graham Number ($33.01) and Intrinsic Value ($82.31). While the company exhibits severe operational anomalies—specifically a -69.90% revenue collapse and a deeply negative operating margin—the massive earnings growth and low P/E ratio (6.29) suggest the entity is benefiting from significant investment gains rather than core fee income. The high dividend yield of 12.76% is supported by a sustainable payout ratio, though the bearish technical trend (10/100) suggests a period of consolidation or price correction is underway.

Strengths
Extreme undervaluation relative to Graham Number ($33.01) and Intrinsic Value ($82.31)
Very low P/E ratio (6.29) compared to the sector average of 36.83
Strong dividend yield of 12.76% with a manageable payout ratio (65.23%)
Risks
Severe revenue decline (-69.90% YoY) indicating a collapse in core business growth
Poor operational efficiency with an operating margin of -346.83%
Liquidity risk evidenced by a current ratio of 0.73 (below 1.0)

Compare Another Pair

BRK-B vs HQL: Head-to-Head Comparison

This page compares Berkshire Hathaway Inc. (BRK-B) and Abrdn Life Sciences Investors (HQL) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile